PRECISION? PLUS SPINAL CORD STIMULATOR System Receives CE Mark Approval as MRI Conditional

Paris (ots/PRNewswire) -

Boston Scientific Corporation has received CE Mark approval for
use of its PRECISION(TM) PLUS SPINAL CORD STIMULATOR (SCS) System in
patients with the system and are in need for magnetic resonance
imaging (MRI) head-only scans. The PRECISION PLUS SCS System is the
world's first rechargeable SCS device. This approval provides
physicians with an additional diagnostic option for patients with
chronic intractable pain.

"As spinal cord stimulation becomes more widespread for control
of severe disabling refractory pain, it is great to know that --
should the need arise -- head-only MRI scans can be safely performed
in patients with the PRECISION PLUS SCS System," said Dr. Simon
Thomson FFPMRCA, consultant in pain medicine and neuromodulation at
Basildon and Thurrock University Hospitals in the United Kingdom.

Chronic intractable pain is continuous pain that has lasted more
than six months. Living in constant pain for an extended period of
time can have a devastating impact on quality of life for many
patients. Without relief, or the hope for relief, many patients lose
the ability to sleep, work, and function normally. Chronic pain
affects one in five adults in Europe, or about 95 million people 15
to 64 years of age.

"We are pleased to announce that patients implanted with the
PRECISION PLUS SCS System will now be able to undergo MRI head
scans," said Michael Onuscheck, senior vice president and president
of Europe, Middle East and Africa at Boston Scientific. "We
understand the need to provide physicians the necessary options to be
able to manage their patients' care and believe this new MRI labeling
will play a role for them."

Spinal cord stimulation is a reversible therapy that manages pain
through an implantable pulse generator (IPG) and thin wires called
electrodes, or "leads," that are implanted in the spinal column. The
device electrically stimulates specific nerves of the spinal cord to
mask the brain's perception of specific pain signals that move up the
spinal cord. To date, about 350,000 patients with chronic pain have
been treated worldwide with SCS therapy.

About the PRECISION(TM) PLUSSCS System

The PRECISION PLUS SCS System was approved in the United States
in 2004 and received approval in Europe and Canada in 2005. The
system is the world's first rechargeable IPG. Today, more than 60,000
patients worldwide have been treated using this system. When compared
to non-rechargeable SCS systems, rechargeable SCS systems may offer
clinical benefits by extending therapeutic longevity and therefore
avoiding frequent replacement surgeries and complications that may
arise from repeated surgeries.

All cited trademarks are the property of their respective owners.
Caution: The law restricts these devices to sale by or on the order
of a physician. Inactions, contraindications, warnings, and
instructions for use can be found on the product labeling supplied
with each device. Information is for use only in countries with
applicable health authority product registrations.

About Boston Scientific Neuromodulation

Boston Scientific Neuromodulation is an innovation leader in
implantable pain management technology. Through its investments in
technology, clinical science, and world-class service, Boston
Scientific Neuromodulation is committed to making life smoother for
physicians and patients. For more information on PRECISION PLUS SCS
System technology, visit http://www.ControlYourPain.com.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices that are used in a broad range of
interventional medical specialties. For more information, please
visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E
of the Securities Exchange Act of 1934. Forward-looking statements
may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words. These
forward-looking statements are based on our beliefs, assumptions and
estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These
forward-looking statements include, among other things, statements
regarding markets for our products, new product indications,
regulatory approvals, clinical trials, product performance and
competitive offerings. If our underlying assumptions turn out to be
incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections
expressed or implied by our forward-looking statements. These
factors, in some cases, have affected and in the future (together
with other factors) could affect our ability to implement our
business strategy and may cause actual results to differ materially
from those contemplated by the statements expressed in this press
release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All of
these factors are difficult or impossible to predict accurately and
many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties that
may affect our future operations, see Part I, Item 1A - Risk Factors
in our most recent Annual Report on Form 10-K filed with the
Securities and Exchange Commission, which we may update in Part II,
Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have
filed or will file hereafter. We disclaim any intention or obligation
to publicly update or revise any forward-looking statements to
reflect any change in our expectations or in events, conditions or
circumstances on which those expectations may be based, or that may
affect the likelihood that actual results will differ from those
contained in the forward-looking statements. This cautionary
statement is applicable to all forward-looking statements contained
in this document.

ots Originaltext: Boston Scientific Corporation
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Simonetta Balbi, +393387936422 (mobile), Media Relations
EMEA, Boston Scientific Corporation, Simonetta.balbi@bsci.com ;
Steven
Campanini, +1-508-652-5740 (office), Media Relations, Boston
Scientific
Corporation, steven.campanini@bsci.com ; Michael Campbell,
+1-508-650-8023
(office), Investor Relations, Boston Scientific Corporation,
investor_relations@bsci.com